Renovaro Biosciences Inc (RENB) - Total Liabilities

Latest as of June 2025: $29.58 Million USD

Based on the latest financial reports, Renovaro Biosciences Inc (RENB) has total liabilities worth $29.58 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore RENB long-term investments to assets to see how much of total assets are deployed in long-term investments.

Renovaro Biosciences Inc - Total Liabilities Trend (2011–2025)

This chart illustrates how Renovaro Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Renovaro Biosciences Inc.

Renovaro Biosciences Inc Competitors by Total Liabilities

The table below lists competitors of Renovaro Biosciences Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Odessa Minerals Ltd AU:ODE	Australia	AU$165.72K
Gediz Ambalaj Sanayi ve Ticaret AS IS:GEDZA	Turkey	TL223.98 Million
Softing AG XETRA:SYT	Germany	€50.05 Million
Unlimited Travel Group UTG AB (publ) ST:UTG	Sweden	Skr492.63 Million
Thai O.P.P. Public Company Limited BK:TOPP	Thailand	฿350.88 Million
Aware Inc NASDAQ:AWRE	USA	$8.96 Million
CompuLab Ltd TA:CLAB	Israel	ILA24.65 Million
Metal Energy Corp V:MERG	Canada	CA$4.10 Million

Liability Composition Analysis (2011–2025)

This chart breaks down Renovaro Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Renovaro Biosciences Inc to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.04	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	-1.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	3.59	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Renovaro Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Renovaro Biosciences Inc (2011–2025)

The table below shows the annual total liabilities of Renovaro Biosciences Inc from 2011 to 2025.

Year	Total Liabilities	Change
2025-06-30	$31.15 Million	0.00%
2024-06-30	$31.15 Million	+164.03%
2023-06-30	$11.80 Million	-1.79%
2022-06-30	$12.01 Million	-19.60%
2021-06-30	$14.94 Million	+26.31%
2020-06-30	$11.83 Million	+74.55%
2019-06-30	$6.78 Million	-71.48%
2018-06-30	$23.76 Million	+694.96%
2017-06-30	$2.99 Million	+98.21%
2016-06-30	$1.51 Million	-14.19%
2015-06-30	$1.76 Million	-16.30%
2014-06-30	$2.10 Million	+2848.11%
2013-06-30	$71.23K	+161.55%
2012-06-30	$27.23K	+211.79%
2011-06-30	$8.73K	--

About Renovaro Biosciences Inc

NASDAQ:RENB USA Biotechnology

Market Cap

$26.19 Million

Market Cap Rank

#24304 Global

#5231 in USA

Share Price

$1.13

Change (1 day)

-8.87%

52-Week Range

$0.13 - $1.42

All Time High

$12.55